269 related articles for article (PubMed ID: 32044178)
21. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice.
Van Belle AB; de Heusch M; Lemaire MM; Hendrickx E; Warnier G; Dunussi-Joannopoulos K; Fouser LA; Renauld JC; Dumoutier L
J Immunol; 2012 Jan; 188(1):462-9. PubMed ID: 22131335
[TBL] [Abstract][Full Text] [Related]
22. A Western Diet, but Not a High-Fat and Low-Sugar Diet, Predisposes Mice to Enhanced Susceptibility to Imiquimod-Induced Psoriasiform Dermatitis.
Yu S; Wu X; Zhou Y; Sheng L; Jena PK; Han D; Wan YJY; Hwang ST
J Invest Dermatol; 2019 Jun; 139(6):1404-1407. PubMed ID: 30571973
[No Abstract] [Full Text] [Related]
23. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells.
Kim JH; Choi YJ; Lee BH; Song MY; Ban CY; Kim J; Park J; Kim SE; Kim TG; Park SH; Kim HP; Sung YC; Kim SC; Shin EC
J Allergy Clin Immunol; 2016 May; 137(5):1466-1476.e3. PubMed ID: 26824999
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of NLRP3 inflammasome-mediated pyroptosis in macrophage by cycloastragenol contributes to amelioration of imiquimod-induced psoriasis-like skin inflammation in mice.
Deng G; Chen W; Wang P; Zhan T; Zheng W; Gu Z; Wang X; Ji X; Sun Y
Int Immunopharmacol; 2019 Sep; 74():105682. PubMed ID: 31203155
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of IL-17-committed T cells in a murine psoriasis model by a vitamin D analogue.
Kusuba N; Kitoh A; Dainichi T; Honda T; Otsuka A; Egawa G; Nakajima S; Miyachi Y; Kabashima K
J Allergy Clin Immunol; 2018 Mar; 141(3):972-981.e10. PubMed ID: 28870465
[TBL] [Abstract][Full Text] [Related]
26.
Bezdek S; Leng L; Busch H; Mousavi S; Rades D; Dahlke M; Zillikens D; Bucala R; Sadik CD
Front Immunol; 2018; 9():2262. PubMed ID: 30333830
[TBL] [Abstract][Full Text] [Related]
27. A monocyte-keratinocyte-derived co-culture assay accurately identifies efficacies of BET inhibitors as therapeutic candidates for psoriasiform dermatitis.
Wu X; Shi Z; Hsu DK; Chong J; Huynh M; Mendoza L; Yamada D; Hwang ST
J Dermatol Sci; 2020 Oct; 100(1):31-38. PubMed ID: 32900573
[TBL] [Abstract][Full Text] [Related]
28. A requirement for slc15a4 in imiquimod-induced systemic inflammation and psoriasiform inflammation in mice.
Griffith AD; Zaidi AK; Pietro A; Hadiono M; Yang JS; Davis R; Popkin DL
Sci Rep; 2018 Sep; 8(1):14451. PubMed ID: 30262916
[TBL] [Abstract][Full Text] [Related]
29. Resident and monocyte-derived Langerhans cells are required for imiquimod-induced psoriasis-like dermatitis model.
Lee M; Kim SH; Kim TG; Park J; Lee JW; Lee MG
J Dermatol Sci; 2018 Jul; 91(1):52-59. PubMed ID: 29655588
[TBL] [Abstract][Full Text] [Related]
30. Effect of γ-secretase inhibitor on Th17 cell differentiation and function of mouse psoriasis-like skin inflammation.
Ma L; Xue H; Qi R; Wang Y; Yuan L
J Transl Med; 2018 Mar; 16(1):59. PubMed ID: 29523162
[TBL] [Abstract][Full Text] [Related]
31. Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing γδ T cells.
Xie XJ; Di TT; Wang Y; Wang MX; Meng YJ; Lin Y; Xu XL; Li P; Zhao JX
Mol Immunol; 2018 Sep; 101():386-395. PubMed ID: 30064075
[TBL] [Abstract][Full Text] [Related]
32. Toll-Like Receptor 7 Agonist-Induced Dermatitis Causes Severe Dextran Sulfate Sodium Colitis by Altering the Gut Microbiome and Immune Cells.
Kiyohara H; Sujino T; Teratani T; Miyamoto K; Arai MM; Nomura E; Harada Y; Aoki R; Koda Y; Mikami Y; Mizuno S; Naganuma M; Hisamatsu T; Kanai T
Cell Mol Gastroenterol Hepatol; 2019; 7(1):135-156. PubMed ID: 30510995
[TBL] [Abstract][Full Text] [Related]
33. The Role of PD-L1 on Langerhans Cells in the Regulation of Psoriasis.
Tanaka R; Ichimura Y; Kubota N; Konishi R; Nakamura Y; Mizuno S; Takahashi S; Fujimoto M; Nomura T; Okiyama N
J Invest Dermatol; 2022 Dec; 142(12):3167-3174.e9. PubMed ID: 35803322
[TBL] [Abstract][Full Text] [Related]
34. TLR2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation through Decrease in Regulatory T Cells and Impaired IL-10 Production.
Nakao M; Sugaya M; Fujita H; Miyagaki T; Morimura S; Shibata S; Asano Y; Sato S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202847
[TBL] [Abstract][Full Text] [Related]
35. Bcat2-Mediated Branched-Chain Amino Acid Catabolism Is Linked to the Aggravated Inflammation in Obese with Psoriasis Mice.
Wang Y; Zhao N; Meng Y; Chen J; Qi C; Hu X; Zhu H; Yang D; Zhang X; Ma H; Zhao J; Di T; Li P; Wang Y
Mol Nutr Food Res; 2024 Apr; 68(8):e2300720. PubMed ID: 38581348
[TBL] [Abstract][Full Text] [Related]
36. Transient receptor potential ankyrin 1 (TRPA1) positively regulates imiquimod-induced, psoriasiform dermal inflammation in mice.
Zhou Y; Han D; Follansbee T; Wu X; Yu S; Wang B; Shi Z; Domocos DT; Carstens M; Carstens E; Hwang ST
J Cell Mol Med; 2019 Jul; 23(7):4819-4828. PubMed ID: 31111624
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
[TBL] [Abstract][Full Text] [Related]
38. C5a/C5aR1 mediates IMQ-induced psoriasiform skin inflammation by promoting IL-17A production from γδ-T cells.
Zheng QY; Xu F; Yang Y; Sun DD; Zhong Y; Wu S; Li GQ; Gao WW; Wang T; Xu GL; Liang SJ
FASEB J; 2020 Aug; 34(8):10590-10604. PubMed ID: 32557852
[TBL] [Abstract][Full Text] [Related]
39. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
Huang SW; Chen YJ; Wang ST; Ho LW; Kao JK; Narita M; Takahashi M; Wu CY; Cheng HY; Shieh JJ
J Dermatol Sci; 2016 Oct; 84(1):59-70. PubMed ID: 27449383
[TBL] [Abstract][Full Text] [Related]
40. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
